1
|
Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo. Cancer Immunol Immunother 2020; 70:1569-1581. [PMID: 33225419 DOI: 10.1007/s00262-020-02780-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Accepted: 10/22/2020] [Indexed: 01/13/2023]
Abstract
Targeted cancer therapy with monoclonal antibodies has proven successful for different cancer types but is limited by the availability of suitable antibody targets. CD43s, a unique sialylated form of CD43 expressed by hematologic malignancies, is a recently identified target and antibodies interacting with CD43s may have therapeutic potential against acute myeloid leukemia (AML) and myelodysplastic syndrome. CD43s is recognized by the human antibody AT1413, that was derived from a high-risk AML patient who successfully cleared leukemia after allogeneic stem cell transplantation. Here we observed that AT1413 binds also to certain non-hematopoietic tumor cells, particularly melanoma and breast cancer. AT1413 immune precipitated CD43s from melanoma cells confirming that it recognizes the same target on melanoma as on AML. AT1413 induced antibody-dependent cellular cytotoxicity against short-term cultured patient-derived melanoma samples. However, AT1413 was unable to affect the growth of melanoma cells in vivo. To increase the efficacy of AT1413 as a therapeutic antibody, we generated two different formats of bispecific T-cell engaging antibodies (TCEs): one binding bivalently (bTCE) and the other monovalently (knob-in-hole; KiH) to both CD43s and CD3ε. In vitro, these TCEs redirected T-cell cytotoxicity against melanoma cells with differences in potencies. To investigate their effects in vivo, we grafted mice that harbor a human immune system with the melanoma cell line A375. Treatment with both AT1413 bTCE and AT1413 KiH significantly reduced tumor outgrowth in these mice. These data indicate a broad therapeutic potential of AT1413 that includes AML and CD43s-expressing solid tumors that originate from CD43-negative tissues.
Collapse
|
2
|
582P Preclinical development of AT1412, a patient derived CD9 antibody that does not induce thrombosis for treatment of precursor B ALL. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.696] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
3
|
580P AT1412, a patient-derived CD9 antibody promotes tumour immune infiltration and induces tumour rejection. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
4
|
Abstract 542: T-cell engager bispecific formats of an AML patient-derived antibody targeting a unique sialylated CD43 epitope induce kill of melanoma cells in vitro and in vivo. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction CD43s, a unique sialylated form of CD43 expressed by myeloid malignancies, is a novel target and AT1413, an antibody targeting CD43s was shown to have therapeutic potential against acute myeloid leukemia (AML) and myelodysplastic syndrome. CD43s is recognized by the human antibody AT1413, that was isolated from a high-risk AML patient who successfully cleared the leukemia after allogeneic stem cell transplantation. Because CD43 is also expressed in non-hematopoietic cells we studied whether CD43s is also present and can also be targeted on non-hematopoietic tumors.
Materials and methods AT1413 binding on a panel of tumor cell lines was analyzed by flow cytometry. AT1413 was constructed into a bispecific T-cell engaging format (AT1413 bTCE) by linking the full-length AT1413 IgG to two single chain variable fragments against CD3ϵ with a combination of site-specific enzymatic and chemical coupling. A monovalent T-cell engager was produced as heterotrimer consisting of one AT1413 monovalent chain and one anti-CD3 scFV fused to AT1413 monovalent chain. Point mutations in the IgG heavy chain were introduced to prevent interactions between AT1413 T-cell engagers and Fc-receptors. The cytotoxicity-inducing activities were established using PBMCs as effector and tumor cells as target cells using standard cytotoxic assays in vitro and in vivo in a mouse model carrying human immune cells.
Results We observed that AT1413 binds to non-hematopoietic tumor cells, such as melanoma and breast cancer. AT1413 immune precipitated CD43s from melanoma cells confirming that it recognizes the same target on melanoma as on AML. AT1413 induced antibody dependent cellular cytotoxicity against melanoma cell lines and primary melanoma samples. However, AT1413 was unable to affect growth of melanoma cells in vivo. To increase the efficacy of AT1413 it was formatted as a bispecific T-cell engaging antibody (TCE): one binding bivalently (bTCE) to CD43s and monovalently to CD3ϵ and the other monovalently (KiH) to both CD43s and CD3ϵ. In vitro, these TCEs redirected T-cell cytotoxicity against melanoma cells with different potencies. To investigate their effects in vivo, we grafted mice that harbor a human immune system with the melanoma cell line A375. Treatment with both AT1413 bTCE and AT1413 KiH significantly reduced tumor outgrowth.
Conclusion AT1413 recognizes a sialylated epitope on CD43 shared by melanoma, AML and MDS cells. Two different bispecific TCE forms of AT1413 induce strong anti-tumor cytotoxic activities in vitro and in vivo. These data indicate a broad therapeutic potential of AT1413.
Citation Format: Greta de Jong, Lina Bartels, Martijn Kedde, Els Verdegaal, Marijn A. Gillissen, Sophie E. Levie, Madalina G. Cercel, Susan E. van Hal-van Veen, Christien Fatmawati, Dorien van de Berg, Etsuko Yasuda, Yvonne Claassen, Arjen Q. Bakker, Remko Schotte, Julien Villaudy, Koen Wagner, Hergen Spits, Mette D. Hazenberg, Pauline M. van Helden. T-cell engager bispecific formats of an AML patient-derived antibody targeting a unique sialylated CD43 epitope induce kill of melanoma cells in vitro and in vivo [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 542.
Collapse
|
5
|
Abstract 532: A patient-derived anti-CD9 antibody induces tumor rejection and synergistically enhances anti-PD1 activity. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Adaptive immunity to cancer cells has been shown to form a crucial part of cancer immunotherapy. Recently, the importance of tumor B-cell signatures were shown to correlate with melanoma survival. We investigated whether anti-tumor antibodies could be isolated from a patient with metastatic melanoma that was tumor-free for 6 years following adoptive transfer of ex vivo expanded autologous T cells (Verdegaal 2011).
Methods
Peripheral blood memory B cells were immortalized using AIMM's immmortalisation technology (ectopic Bcl-6 and Bcl-xL; Kwakkenbos 2010) expression and analyzed for the presence of tumor-reactive B cells.
Results
AT1412 antibody was identified by virtue of its differential binding to melanoma cells as compared to healthy melanocytes. AT1412 was found to bind the tetraspanin CD9, a broadly expressed protein involved in multiple cellular activities and disease progression. The crystal structure of the CD9 large extracellular loop in complex with an AT1412 Fab fragment revealed that AT1412 binds the CD9 epitope in an extended and unfolded conformation. In addition to melanoma, AT1412 binds other tumor types including gastric, colon- and pancreatic cancer. AT1412 was shown to induce antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) of cancer cells. In addition, AT1412 demonstrated activation of monocytes, most likely via activation of CD9 on platelets-bound monocytes. In mice carrying a human immune system (HIS-mice; van Lent 2010) AT1412 strongly enhanced tumor rejection of A375 and SKMEL-5 tumor cells. AT1412 treatment was shown to enhance tumor infiltration of CD8 T cells and macrophages. AT1412 efficacy was further synergistically enhanced when combined with an anti-PD1 antibody (nivolumab). Other groups have shown that anti-CD9 antibodies can induce tumor rejection in mice. However, these antibodies could not be advanced due to induction of platelet aggregation. We show that AT1412 does not induce aggregation of both human and cynomolgus platelets. Also affinity matured versions of AT1412 do not induce platelet aggregation, supporting that AT1412 binds a unique epitope on CD9. In addition, we studied the safety of AT1412 during a one month exposure in a weekly administration in cynomolgus monkeys. Besides a transient thrombocytopenia AT1412 was well tolerated up to 10 mg/kg antibody (highest dose tested) and did not lead to other adverse events nor were any coagulation factors affected
Conclusions
Taken together, applying AIMM's proprietary B-cell immortalization technology we isolated antibody AT1412 that targets a unique epitope on CD9. AT1412 was shown to induce tumor rejection as a single agent and enhances the activity of anti-PD-1 antibodies, while not inducing platelet aggregation. One month exposure of AT1412 in monkeys indicated that AT1412 can be safely administered. Preclinical development of AT1412 is ongoing to initiate clinical evaluation in 2020.
Funding
Dutch Cancer Society, grant UVA 2010-4822
Citation Format: Remko Schotte, Julien Villaudy, Martijn Kedde, Wouter Pos, Koen Wagner, Viviana Neviani, Daniel Go, Etsuko Yasuda, Christien Fatmawati, Els Verdegaal, Susan van Hal, Yvonne Claasen, Hans van Eenennaam, Pauline van Helden, Piet Gros, Sjoerd van der Burg, Hergen Spits. A patient-derived anti-CD9 antibody induces tumor rejection and synergistically enhances anti-PD1 activity [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 532.
Collapse
|
6
|
A Chemo-enzymatically Linked Bispecific Antibody Retargets T Cells to a Sialylated Epitope on CD43 in Acute Myeloid Leukemia. Cancer Res 2019; 79:3372-3382. [PMID: 31064847 DOI: 10.1158/0008-5472.can-18-0189] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2018] [Revised: 03/16/2019] [Accepted: 04/30/2019] [Indexed: 11/16/2022]
Abstract
Acute myeloid leukemia (AML) is a high-risk disease with a poor prognosis, particularly in elderly patients. Because current AML treatment relies primarily on untargeted therapies with severe side effects that limit patient eligibility, identification of novel therapeutic AML targets is highly desired. We recently described AT1413, an antibody produced by donor B cells of a patient with AML cured after allogeneic hematopoietic stem cell transplantation. AT1413 binds CD43s, a unique sialylated epitope on CD43, which is weakly expressed on normal myeloid cells and overexpressed on AML cells. Because of its selectivity for AML cells, we considered CD43s as a target for a bispecific T-cell-engaging antibody (bTCE) and generated a bTCE by coupling AT1413 to two T-cell-targeting fragments using chemo-enzymatic linkage. In vitro, AT1413 bTCE efficiently induced T-cell-mediated cytotoxicity toward different AML cell lines and patient-derived AML blasts, whereas endothelial cells with low binding capacity for AT1413 remained unaffected. In the presence of AML cells, AT1413 bTCE induced upregulation of T-cell activation markers, cytokine release, and T-cell proliferation. AT1413 bTCE was also effective in vivo. Mice either coinjected with human peripheral blood mononuclear cells or engrafted with human hematopoietic stem cells [human immune system (HIS) mice] were inoculated with an AML cell line or patient-derived primary AML blasts. AT1413 bTCE treatment strongly inhibited tumor growth and, in HIS mice, had minimal effects on normal human hematopoietic cells. Taken together, our results indicate that CD43s is a promising target for T-cell-engaging antibodies and that AT1413 holds therapeutic potential in a bTCE-format. SIGNIFICANCE: These findings offer preclinical evidence for the therapeutic potential of a bTCE antibody that targets a sialylated epitope on CD43 in AML.
Collapse
|
7
|
14 A patient derived antibody targeting the tetraspanin CD9 inhibits tumour progression and metastasis. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.14] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
8
|
Abstract LB-200: A patient derived antibody targeting the tetraspanin CD9 synergistically inhibits tumor growth with an anti PD1 antibody. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-lb-200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. It is generally accepted that immune reactions against cancer cells can be induced by immunotherapy. Here, we investigated the possibility that an antibody response has contributed to the success of the immunotherapy of a cancer patient.
Methods. A patient with metastatic melanoma was successfully treated by adoptive transfer of ex vivo expanded autologous tumor reactive T cells1. This patient is still tumor free 9 years after treatment. Peripheral blood memory B cells were immortalized by ectopic Bcl-6 and Bcl-xL expression2 and analyzed for the presence of tumor-reactive B cells.
Results. We isolated one B cell clone that produced an antibody, named AT1412, recognizing a novel cell surface epitope on the tetraspanin CD9 which is broadly expressed and involved in multiple cellular activities including proliferation and adherence.
AT1412 bound more strongly to melanoma cells than to melanocytes and other healthy tissues indicating that the AT1412 epitope is overexpressed on tumor cells. In addition, AT1412 strongly reacted with other tumor types including colon, pancreas and, breast cancer. Further analysis revealed that AT1412 favors binding to a clustered state of CD9. CD9 clusters are dependent on palmitoylation and known to be present on metastatic cells3.
Previously published high affinity mouse antibodies targeting human CD9 were found to trigger aggregation of platelets and thus unfit for therapeutic use4. In sharp contrast, AT1412 does not induce platelet aggregation. To address whether AT1412 fails to aggregate platelets because of its low affinity for CD9 we generated high affinity variants of AT1412 using our highly efficient affinity maturation platform. We obtained AT1412 variants with affinities up to 250 fold higher than the wild type AT1412 comparable to that of mouse anti-human CD9 antibodies. These high affinity variants still did not aggregate platelets indicating that the absence of platelet aggregation by AT1412 is due to the spatial arrangement of the AT1412 epitope present on CD9 and not its low affinity.
The antibody was able to reduce growth of melanoma tumors and block metastasis in melanoma xenografted mice. A striking synergistic inhibition of tumor growth was observed in mice that were treated with our CD9 antibody in the presence of a clinically successful anti-PD1 checkpoint inhibitor antibody.
Discussion. These data suggest that the antibody contributed to the success of the immunotherapy in this patient. This antibody could act together with tumor-reactive T cells in eradicating circulating tumor cells and/or preventing settlement of metastatic tumor cells. Importantly, no antibody-related adverse effects were observed during and after treatment of this patient indicating that the antibody is safe for use in humans.
1.
Verdegaal, Cancer Immunol Immunother, 2011
2.
Kwakkenbos, Nat Med, 2010
3.
Yang, JBC, 2006
4.
Boucheix, FEBS Letter, 1983
Citation Format: Remko Schotte, Pauline van Helden, Daniel Go, Christien Fatmawati, Els Verdegaal, Camile Bru, Julien Villaudy, Koen Wagner, Sjoerd van der Burg, Hergen Spits, Wouter Pos. A patient derived antibody targeting the tetraspanin CD9 synergistically inhibits tumor growth with an anti PD1 antibody [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr LB-200. doi:10.1158/1538-7445.AM2017-LB-200
Collapse
|
9
|
Adaptation of a human gut epithelial model in relation to the assessment of clinical pharmacokinetic parameters for selected tyrosine kinase inhibitors. ADMET AND DMPK 2015; 3. [DOI: 10.5599/admet.3.1.169] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/15/2023] Open
|
10
|
Abstract C82: Role of influx and efflux transporters on gut absorption of selected tyrosine kinase inhibitors in a polarized gut epithelium model system. Mol Cancer Ther 2013. [DOI: 10.1158/1535-7163.targ-13-c82] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Tyrosine kinase inhibitors (TKI) are a family of small molecules which inhibit the ATP driven phosphorylation of signaling proteins that normally activate transduction cascades. Aberrations in signal cascades have been linked to the development of tumors and their survival pathways. TKIs tend to be alkali in nature with a correspondingly high pKa (5-8) while absorption properties have been linked to both ABC and Organic Cation Transporters (OCT). Because of their poor solubility, TKI are administered orally but available pharmacokinetic data indicate that in most cases bioavailability is relatively low (∼60% or lower). Despite a molecular weight in a similar range, doses vary significantly: Sunitinib (Sun) - 50 mg/d, Dasatinib (Das) - 150 mg/d, Erlotinib (Erl) - 150 mg/d, Gefitinib (Gef) - 250 mg/d, Crizotinib (Cri) - 250 mg BID and Sorafenib (Sor) - 400 mg BID. Steady state plasma levels vary from 0.13 (Sun), 0.21 (Das), 0.29 (Gef), 0.7 (Cri), 2.54 (Erl) to 12.1 µM (Sor). Variations in intestinal absorption may seriously affect plasma concentrations, tumour exposure and antitumor effect. To investigate the mechanisms behind these differences a well-established model for intestinal transport was used: the human colon cell line, CaCo2, when grown in special coated transwell plates forms a confluent differentiated polarised monolayer resembling gut epithelium. This model was used to determine the permeability of Gef, Erl, Sun, Cri, Sor, and Das, using LC-MS-MS to determine drug concentrations. Absorption from the gut given as the transfer rates from Apical to Basolateral (A/B) sides using 20 µM TKI at the apical side was determined over a 3 hour period. Transfer was linear in this period. Transfer rates varied from about 30 for Cri, 43 for Sun, 209 for Das, 180 for Gef, 223 for Sor, to 479 pmol/hr for Erl. In order to determine the role of ABC pumps, we depleted ATP with azide, which partially reduced transfer of Gef, Sun and Sor, but did not affect Erl. Ko143, a specific ABCG2 inhibitor decreased transfer of Gef and Sor but unexpectedly increased Sun. Remarkably, permeability transfer rates from the basolateral (blood) side to gut (B/A) were much higher (252 for Gef, 621 for Sor, 685 for Sun, 1623 for Erl and 4630 pmol/hr for Das) than A/B transfer. Verapamil, an inhibitor of P-glycoprotein and to some extend OCT1 increased A/B transfer of Sor and Das, but did not affect the transfer of the other compounds. Desipramine, a general OCT inhibitor, did not affect transfer of Erl, increased that of Gef and Cri about 2-fold and that of Sun 1.5-fold, but hardly affected that of Sor and Das. In conclusion, absorption of TKI from the apical side (gut epithelium) is relatively poor, while there was a relatively high negative flow (B/A); this is in line with the low bioavailability of most TKI. Some ABC transporters and OCTs play a role in the absorption, in line with their substrate specificity.
Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C82.
Citation Format: Richard J. Honeywell, Christien Fatmawati, Marita Boeddha, Sarina Hitzerd, Ietje Kathmann, Elisa Giovannetti, Godefridus J. Peters. Role of influx and efflux transporters on gut absorption of selected tyrosine kinase inhibitors in a polarized gut epithelium model system. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C82.
Collapse
|
11
|
Abstract 3785: Human pharmacokinetics (PK) of selected tyrosine kinase inhibitors (TKI) in relation to transport characteristics in a polarized gut epithelium model system. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-3785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
TKI represent the largest group of novel anticancer drugs. Loosely based on a core pyrimidine structure TKI selectively target the ATP activity of a TK. Their poor solubility represents a challenge in administration. TKI are administered orally but available PK indicates that in most cases bioavailability is relatively low (∼60% or lower). Despite a molecular weight in a similar range, doses vary significantly: Sunitinib (Sun) - 50 mg/d, Dasatinib (Das) - 150 mg/d, Erlotinib (Erl) - 150 mg/d, Gefitinib (Gef) - 250 mg/d and Sorafenib (Sor) - 400 mg BID. Steady state plasma levels vary from 0.13 (Sun), 0.21 (Das), 0.29 (Gef), 2.54 (Erl) to 12.1 µM (Sor). In combination Erl increased systemic plasma levels of Sor. Variations in intestinal absorption may seriously affect plasma concentrations, tumour exposure and anti tumour effect. To investigate the mechanisms behind these differences a well established model for intestinal transport was used: the human colon cell line, CaCo2, when grown in special coated Transwell plates forms a confluent differentiated polarised monolayer resembling gut epithelium. This model was used to determine the permeability of Gef, Erl, Sun, Sor, Das and combined Erl/Sor. Absorption from the gut given as the transfer rates from Apical to Basolateral (A/B) sides using 20 µM TKI at the apical side was determined over a 3 hour period. Transfer was linear in this period. Transfer rates varied from 43 for Sun, 209 for Das, 180 for Gef, 223 for Sor, to 479 pmol/hr for Erl. At 10 µM Erl increased transfer rate of Sor from 145 to 185.7 pmol/hr in line with observed plasma levels. In order to determine the role of ABC pumps, we depleted ATP with azide, which partially reduced transfer of Gef, Sun and Sor, but did not affect Erl. Ko143, a specific ABCG2 inhibitor decreased transfer of Gef and Sor but unexpectedly increased Sun. Remarkably, permeability transfer rates from the basolateral (blood) side to gut (B/A) were much higher (252 for Gef, 621 for Sor, 685 for Sun, 1623 for Erl and 4630 pmol/hr for Das) than A/B transfer. In order to explain this difference we determined cellular accumulation in the monolayer cells at the end of the experiments. For the A/B experiments this was undetectable for Erl, 0.79 for Gef, 1.65 for Sor, 11.9 for Sun and 1.1 for Das (pmol/µg protein). For the B/A experiments a proportional decrease in accumulation relative to the observed increased transfer rate was seen with Gef as the exception, with values from undetectable for Erl, 2.1 for Gef, 0.15 for Sor, 4.72 for Sun and 0.26 pmol/µg protein for Das. In conclusion, absorption of TKI from the apical side (gut epithelium) is relatively poor, while there was a relatively high negative flow (B/A); this is in line with the low bioavailability of most TKI. Some ABC transporters play a role in the absorption, in line with their substrate specificity. This may also affect retention of TKI in tumour cells
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3785. doi:1538-7445.AM2012-3785
Collapse
|
12
|
Humoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls. J Med Virol 2011; 83:665-78. [DOI: 10.1002/jmv.21960] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|